Navigation Links
Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBC's Drug Discovery & Development of Innovative Therapeutics Conference
Date:6/30/2008

WESTBOROUGH, Mass. June 30 /PRNewswire/ -- Joseph B. Bolen, Ph.D., CSO of Millennium Pharmaceuticals, will chair the Focus on Cancer track IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition taking place August 4-7 at the World Trade Center Boston & Seaport Hotel in Boston, MA. The cancer track presentations will focus on therapies for Hematology, Lung Cancer, Blood Borne Cancers, and Clinical Biomarkers.

Bolen has confirmed academia speakers including: Kenneth C. Anderson, M.D., Dana Farber Cancer Institute, Harvard Medical School; Bruce E. Johnson, M.D., Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital; Mark A. Israel, M.D., Dartmouth Medical School; Neal Rosen, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center; Massimo Loda, M.D., Dana Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School

Companies also giving technical conference presentations in this cancer track include Alnylam Pharmaceuticals, Amgen, Inc., ARIAD Pharmaceuticals Inc., ArQule, Inc., AstraZeneca R&D Boston, Bristol-Myers Squibb Company, Exelixis Inc, Genzyme Corporation, Infinity Pharmaceuticals, Inc, Merck Research Laboratories, Novartis Institutes for BioMedical Research, OncoMed Pharmaceuticals Inc, The Johnson & Johnson Family of Companies.

Additional conference sessions at Drug Discovery & Development of Innovative Therapeutics conference include:

-- Cardio-Metabolic Disease Drug Discovery and Development

-- Translational Medicine/Research

-- Transforming Technologies

-- Anti-Infective Drug Discovery and Development

-- Neurodegenerative Disease Drug Discovery and Development

-- Inflammation in Drug Discovery and Development

-- Orphan Diseases: Fast-Tracking Orphan Drugs and Scientific Advances -- The Next Generation of Therapeutics: Emerging Biologics, Stem Cells and RNAi

IBC's Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition is an international event that covers topics across multiple therapeutic areas. The event includes over 15 presentations from more than 200 speakers, 150 exhibitors, 13 interactive round table discussions and 4 keynote presentations. For more information please visit http://www.drugdisc.com.

Complete details on this event can be found at http://www.drugdisc.com or to receive a press pass or arrange an interview with a speaker, email Keri Dostie at kdostie@ibcusa.com.

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com.

Contact: Keri Dostie

IBC Life Sciences

508-614-1404

kdostie@ibcusa.com


'/>"/>
SOURCE IBC Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
2. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
3. SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors
4. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
5. J. Craig Venter Institute Names Robert Friedman, Ph.D., Deputy Director of West Coast Facility
6. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
7. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
8. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
9. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
10. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... in healthcare information exchange, today announced that Charles W. Stellar has been named by ... WEDI’s interim CEO since January 2016. As an executive leader with more than 35 ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical ... (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for the ... granted by the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative ...
(Date:5/24/2016)... AVIV, Israel , May 24, 2016   MedyMatch ... providing physicians with artificial intelligence, real-time decision support tools in ... to present at the 2016 Israeli Advanced Technology Industries (IATI) ... of Israel,s 15th National Life Sciences ... 26th at the David Intercontinental Hotel in Tel ...
(Date:5/24/2016)... Rockville, Maryland (PRWEB) , ... May 24, 2016 ... ... introduction of a newly re-branded identity. The new Media Cybernetics corporate branding reflects ... the world of imaging and image analysis. The re-branding components include a crisp, ...
Breaking Biology Technology:
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ... at AP Images ( http://www.apimages.com ) - Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ... Hanover next week.   --> ... to produce the new refugee identity cards. DERMALOG will be unveiling ...
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI Strategic ... of Innovation, Research & Development, Leadership in Education, and, ... is the 9 th year of the FLEXI ... companies and individuals from past years . Judging ... a pre-described set of criteria, by a panel of ...
Breaking Biology News(10 mins):